FDA rejects serelaxin for acute heart failure

The Food and Drug Administration has decided that more evidence of serelaxin’s efficacy as a treatment for acute heart failure is needed before the drug can be approved in the United States, Novartis...

Field of Interest: Cardiology
Type: News Item

Remote monitoring of devices boosted survival

SAN FRANCISCO – Patients with implantable pacemakers and defibrillators who engage in remote monitoring at more than 75% adherence rates have a 2.4-fold higher rate of survival than those who do not...

Field of Interest: Cardiology
Type: News Item

Apixiban for VTE reduced subsequent hospitalizations

WASHINGTON – Treating acute venous thromboembolism with the fixed-dose oral factor Xa inhibitor apixaban significantly reduces subsequent all-cause hospitalizations, compared with conventional...

Field of Interest: Cardiology
Type: News Item

FDA declines to approve IV antiplatelet drug cangrelor

The Food and Drug Administration has rejected the approval of the intravenous antiplatelet drug cangrelor, suggesting that the company provide more data, according to the drug’s manufacturer. The...

Field of Interest: Cardiology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.